Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Mackean, Melanie"" wg kryterium: Autor


Wyświetlanie 1-48 z 48
Tytuł :
Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma
Autorzy :
Hollis, Robert L.
Stanley, Barbara
Iida, Yasushi
Thomson, John
Churchman, Michael
Rye, Tzyvia
Mackean, Melanie
Nussey, Fiona
Gourley, Charlie
Herrington, C. Simon
Pokaż więcej
Temat :
androgen receptor
estrogen receptor
ovarian cancer
body mass index
endometrioid ovarian carcinoma
progesterone receptor
Article
Źródło :
Hollis, R, Stanley, B, Iida, Y, Thomson, J, Churchman, M, Rye, T, Mackean, M J, Nussey, F, Gourley, C & Herrington, C 2019, ' Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma ', Gynecologic Oncology, vol. 155, no. 2, pp. 318-323 . https://doi.org/10.1016/j.ygyno.2019.09.001
Opis pliku :
application/pdf
Tytuł :
Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors
Autorzy :
Stanley, Barbara
Hollis, Robb
Nunes, Hugo
Towler, Jonathan D
Yan, Xiangfei
Rye, Tzyvia
Dawson, Carol
Mackean, Melanie J
Nussey, Fiona
Churchman, Michael
Herrington, Charles
Gourley, Charles
Pokaż więcej
Źródło :
Stanley, B, Hollis, R, Nunes, H, Towler, J D, Yan, X, Rye, T, Dawson, C, Mackean, M J, Nussey, F, Churchman, M, Herrington, C & Gourley, C 2018, ' Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors ', Gynecologic Oncology . https://doi.org/10.1016/j.ygyno.2018.11.030
Opis pliku :
application/pdf
Tytuł :
Routine germline BRCA1 and BRCA2 testing in ovarian carcinoma patients: analysis of the Scottish real life experience
Autorzy :
Rust, Kelly
Spiliopoulou, Pavlina
Yuan Tang, Chee
Bell, Christine
Stirling, Diane
Fife Phang, Tze hui
Davidson, Rosemarie
MacKean, Melanie
Nussey, Fiona
Glasspool, Ros
Reed, Nick
Sadozye, Azmat
Porteous, Mary
McGoldrick, Trevor
Ferguson, Michelle
Miedzybrodzka, Zofia
McNeish, Iain A.
Gourley, Charles
Pokaż więcej
Temat :
BRCA1
BRCA2
RAD51C
RAD51D
Ovarian cancer
Źródło :
Rust, K, Spiliopoulou, P, Yuan Tang, C, Bell, C, Stirling, D, Fife Phang, T H, Davidson, R, MacKean, M, Nussey, F, Glasspool, R, Reed, N, Sadozye, A, Porteous, M, McGoldrick, T, Ferguson, M, Miedzybrodzka, Z, McNeish, I A & Gourley, C 2018, ' Routine germline BRCA1 and BRCA2 testing in ovarian carcinoma patients: analysis of the Scottish real life experience ', BJOG: An International Journal of Obstetrics and Gynaecology . https://doi.org/10.1111/1471-0528.15171
Opis pliku :
application/vnd.openxmlformats-officedocument.wordprocessingml.document
Tytuł :
Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations
Autorzy :
Gourley, Charlie
Hollis, Robert L.
Meynert, Alison M.
Churchman, Michael
Rye, Tzyvia
Mackean, Melanie
Nussey, Fiona
Arends, Mark J.
Sims, Andrew H.
Semple, Colin A.
Herrington, C. Simon
Pokaż więcej
Temat :
Retrospective Studies
Research Article
skin and connective tissue diseases
Doxorubicin/analogs & derivatives
Cystadenocarcinoma, Serous/drug therapy
BRCA2 Protein/genetics
endocrine system diseases
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Neoplasm Grading
BRCA1 Protein/genetics
Polymorphism, Single Nucleotide
Survival Rate
BRCA1
Female
BRCA2
Polyethylene Glycols/therapeutic use
Ovarian cancer
Ovarian Neoplasms/drug therapy
Aged
Middle Aged
Biomarkers, Tumor/genetics
Mutation
Follow-Up Studies
PLDH
RC254-282
Genetic Predisposition to Disease
Adult
Aged, 80 and over
Antibiotics, Antineoplastic/therapeutic use
Humans
Źródło :
Hollis, R L, Meynert, A, Churchman, M, Rye, T, Mackean, M, Nussey, F, Arends, M, Sims, A, Semple, C, Herrington, C & Gourley, C 2018, ' Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations ', BMC Cancer, vol. 18, no. 1, pp. 16 . https://doi.org/10.1186/s12885-017-3981-2
BMC Cancer, Vol 18, Iss 1, Pp 1-8 (2018)
Opis pliku :
application/pdf
Tytuł :
Additional file 1: Figure S1. of Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations
Autorzy :
Hollis, Robert
Meynert, Alison
Churchman, Michael
Tzyvia Rye
Mackean, Melanie
Nussey, Fiona
Arends, Mark
Sims, Andrew
Semple, Colin
C. Simon Herrington
Gourley, Charlie
Pokaż więcej
Temat :
Biochemistry
Genetics
Evolutionary Biology
39999 Chemical Sciences not elsewhere classified
69999 Biological Sciences not elsewhere classified
Cancer
60506 Virology
Tytuł :
103 - Scottish Immunotherapy Prognostic Score: biomarker of systemic inflammation predicts response to first-line pembrolizumab for metastatic non-small cell lung cancer.
Autorzy :
Ding, Tze-en Grace (AUTHOR)
Thomson, Findlay (AUTHOR)
Stratton, Cory (AUTHOR)
Cumming, Kirsten (AUTHOR)
Barrie, Colin (AUTHOR)
Maclennan, Kirsty (AUTHOR)
Evans, Tamasin (AUTHOR)
Campbell, Sorcha (AUTHOR)
Tufail, Aisha (AUTHOR)
Mackean, Melanie (AUTHOR)
Phillips, Iain (AUTHOR)
Stares, Mark (AUTHOR)
Pokaż więcej
Źródło :
Lung Cancer (01695002). Jun2021:Supplement 1, Vol. 156, pS43-S43. 1p.
Czasopismo naukowe
Tytuł :
80 - Real world prospective data on tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor mutation positive non-small cell lung cancer at the Edinburgh Cancer Centre.
Autorzy :
Swan, Amanda (AUTHOR)
Boh, Zhuang (AUTHOR)
Patrizio, Ailsa (AUTHOR)
Phillips, Iain (AUTHOR)
Evans, Tamasin (AUTHOR)
MacLennan, Kirsty (AUTHOR)
Tufail, Aisha (AUTHOR)
Barrie, Colin (AUTHOR)
MacKean, Melanie (AUTHOR)
Pokaż więcej
Źródło :
Lung Cancer (01695002). Jun2021:Supplement 1, Vol. 156, pS32-S32. 1p.
Czasopismo naukowe
Tytuł :
Structural Variants at the BRCA1/2 Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma.
Autorzy :
Ewing A; MRC Human Genetics Unit, MRC IGMM, University of Edinburgh, Edinburgh, Scotland, United Kingdom. .
Meynert A; MRC Human Genetics Unit, MRC IGMM, University of Edinburgh, Edinburgh, Scotland, United Kingdom.
Churchman M; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, MRC IGMM, University of Edinburgh, Edinburgh, Scotland, United Kingdom.
Grimes GR; MRC Human Genetics Unit, MRC IGMM, University of Edinburgh, Edinburgh, Scotland, United Kingdom.
Hollis RL; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, MRC IGMM, University of Edinburgh, Edinburgh, Scotland, United Kingdom.
Herrington CS; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, MRC IGMM, University of Edinburgh, Edinburgh, Scotland, United Kingdom.; Edinburgh Pathology, Cancer Research UK Edinburgh Centre, MRC IGMM, University of Edinburgh, Edinburgh, Scotland, United Kingdom.
Rye T; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, MRC IGMM, University of Edinburgh, Edinburgh, Scotland, United Kingdom.
Bartos C; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, MRC IGMM, University of Edinburgh, Edinburgh, Scotland, United Kingdom.
Croy I; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, MRC IGMM, University of Edinburgh, Edinburgh, Scotland, United Kingdom.
Ferguson M; Department of Oncology, Ninewells Hospital, NHS Tayside, Dundee, Scotland, United Kingdom.; Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee, Scotland, United Kingdom.
Lennie M; Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee, Scotland, United Kingdom.
McGoldrick T; Department of Oncology, Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom.; Institute of Education for Medical and Dental Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, Scotland, United Kingdom.
McPhail N; Department of Oncology, Raigmore Hospital, NHS Highland, Inverness, Scotland, United Kingdom.
Siddiqui N; Department of Gynaecological Oncology, Glasgow Royal Infirmary, Glasgow, Scotland, United Kingdom.
Dowson S; Institute of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom.
Glasspool R; Beatson West of Scotland Cancer Centre and University of Glasgow, Glasgow, Scotland, United Kingdom.
Mackean M; Edinburgh Cancer Centre, Western General Hospital, NHS Lothian, Edinburgh, Scotland, United Kingdom.
Nussey F; Edinburgh Cancer Centre, Western General Hospital, NHS Lothian, Edinburgh, Scotland, United Kingdom.
McDade B; Institute of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom.
Ennis D; Institute of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom.; Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, England, United Kingdom.
McMahon L; Precision Medicine Scotland (PMS-IC), Queen Elizabeth University Hospital, Glasgow, Scotland, United Kingdom.
Matakidou A; Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, England, United Kingdom.
Dougherty B; Translational Medicine, Oncology R&D, AstraZeneca, Waltham, Massachusetts.
March R; Precision Medicine, Oncology R&D, AstraZeneca, Cambridge, England, United Kingdom.
Barrett JC; Translational Medicine, Oncology R&D, AstraZeneca, Waltham, Massachusetts.
McNeish IA; Institute of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom.; Beatson West of Scotland Cancer Centre and University of Glasgow, Glasgow, Scotland, United Kingdom.; Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, England, United Kingdom.
Biankin AV; Institute of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom.; West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow, Scotland, United Kingdom.; South Western Sydney Clinical School, Faculty of Medicine, University of NSW, Liverpool, New South Wales, Australia.
Roxburgh P; Institute of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom.; Beatson West of Scotland Cancer Centre and University of Glasgow, Glasgow, Scotland, United Kingdom.
Gourley C; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, MRC IGMM, University of Edinburgh, Edinburgh, Scotland, United Kingdom.
Semple CA; MRC Human Genetics Unit, MRC IGMM, University of Edinburgh, Edinburgh, Scotland, United Kingdom.
Pokaż więcej
Corporate Authors :
Scottish Genomes Partnership
Źródło :
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Jun 01; Vol. 27 (11), pp. 3201-3214. Date of Electronic Publication: 2021 Mar 19.
Typ publikacji :
Journal Article
Czasopismo naukowe
    Wyświetlanie 1-48 z 48

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies